Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mannosylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating Eucommia ulmoides polysaccharides (EOPP) were developed as a targeted immunomodulatory delivery system. In vitro evaluations confirmed that EOPP exhibited low cytotoxicity toward spleen lymphocytes while significantly increasing their proliferation and cytokine secretion (IL-6 and IFN-γ). When co-delivered with ovalbumin (MN-EOPP/OVA), the system further enhanced the secretion of TNF-α, IL-12, IL-6, and IFN-γ by immune cells and induced cytoskeletal remodeling and maturation in bone marrow-derived dendritic cells (BMDCs). Transcriptomic profiling revealed significant upregulation of immune-related genes, with KEGG and PPI analyses identifying activation of key signaling pathways, including MAPK (ERK, p38, JNK) and NF-κB. These pathways drive the expression of genes involved in antigen processing and dendritic cell function. Overall, MN-EOPP/OVA effectively enhanced both humoral and cellular immune responses by synergistic delivery of antigen and immunopotentiator, supporting its potential as a next-generation vaccine adjuvant strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.colsurfb.2025.115002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel treatment for diabetic nephropathy: Folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models.
Nanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDFFolic Acid-Chitosan-PLGA Nano Delivery System Against Liver Cancer Cells: In Vitro Studies.
J Biochem Mol Toxicol
September 2025
Department of Biology, SR.C., Islamic Azad University, Tehran, Iran.
Among cancers, liver cancer is the fourth leading cause of mortality worldwide and drawbacks of conventional approaches could not inhibit this cancer. Thus, an efficient folic acid (FA)-functionalized chitosan (CS)-poly lactic-co-glycolic acid (PLGA) nanocarrier was fabricated for delivery of sodium butyrate (NB) therapeutics to HepG2 liver cancer cells. The fabricated CS-NB-PLGA-FA nanocarrier was characterized by FT-IR, DLS, TEM, and TGA.
View Article and Find Full Text PDFCholesterol-Functionalized Porous PLA Microparticles for Enhanced Drug Delivery.
ACS Appl Bio Mater
September 2025
Innovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.
A drug delivery platform based on highly porous poly(lactic acid) (PLA) microparticles functionalized with amphiphilic poly(ethylene glycol)-cholesterol (PEG-Chol) has been developed and successfully validated . This hybrid system addresses key limitations of conventional PLA and poly(lactide--glycolide) (PLGA) nanoparticles, providing better encapsulation and sustained drug release. The incorporation of PEG-Chol provides both enhanced aqueous dispersibility for prolonged circulation and membrane-anchoring capabilities, thereby promoting cellular interaction and endocytosis.
View Article and Find Full Text PDFThe Effects of PLGA Nanoparticles Containing Different Growth Factors on Neural Stem Cell Differentiation and Their Transition Efficiency After Targeting With TRF.
CNS Neurosci Ther
September 2025
Center for Stem Cell & Gene Therapies Research & Practice, Kocaeli University, Kocaeli, Turkey.
Aims: Nanoparticle-mediated drug delivery systems are being investigated for the controlled release of drugs to treat neurodegenerative diseases (ND). We aimed to investigate the effects of poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) containing different growth factors (GFs) on rat brain-derived neural stem cells (NSCs) in vitro differentiation, providing insights that may contribute to future approaches for treating Parkinson's disease.
Methods: Three different PLGA-NPs loaded with Brain-Derived Neurotrophic Factor (BDNF), Glial-Derived Neurotrophic Factor (GDNF), and Transforming Growth Factor beta 3 (TGF-β3) were developed and characterized in terms of size, zeta potential, encapsulation efficiency, and release profile.
Nephelometry as a simple tool to monitor the disassembly of polymeric nanoparticles.
Anal Methods
September 2025
Vrije Universiteit Amsterdam, Department of Chemistry and Pharmaceutical Sciences, Amsterdam Institute of Molecular and Life Sciences (AIMMS), Division of BioAnalytical Chemistry, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
Polymer-based nanoparticles (PNPs) find wide application in material and pharmaceutical sciences. In order to determine the quality of produced PNPs and understand their function, analytical characterization is essential. Recently, two-dimensional liquid chromatography (2D-LC) has been introduced as an effective means to probe multiple PNP properties, such as size and composition, in an integrated manner.
View Article and Find Full Text PDF